Drugs / Sapu003
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07369505 | Dec 2025 → Jun 2026 overdue | breast carcinoma, hepatocellular carcinoma, neuroendocrine neoplasm, renal cell carcinoma +1 | SAPU NANO (US) LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sapu003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07369505 ↗ |
| Route | Intravenous | “Sapu003 weekly IV at 5, 7.5 or 10 mg/m²” NCT07369505 ↗ |